New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT06115642
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called HLX43, an antibody-drug conjugate that targets PD-L1, in people with advanced or metastatic solid tumors that have not responded to standard treatments. Participants also receive another immunotherapy drug, serplulimab (HLX10). The main goals are to check safety, find the right dose, and see if tumors shrink. About 367 people will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HLX43 (anti-PD-L1 antibody-drug conjugate) and HLX10 (serplulimab)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early Phase 1 trial, so safety and effectiveness are not yet proven. The drug may cause serious side effects or not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
-
Georgetown University
Washington D.C., District of Columbia, 20057, United States
-
Kindai University Hospital
Sayama, Osaka, 589-8511, Japan
-
MD Anderson Medical Center
Houston, Texas, 77030, United States
-
National Cancer Center Hospital
Tokyo, 104-0045, Japan
-
Okayama University Hospital
Okayama, 700-8558, Japan
-
Sendai Kousei Hospital
Sendai, Miyagi, 980-0873, Japan
-
Shizuoka Cancer Center
Shizuoka, 411-8777, Japan
-
Stanford University
Stanford, California, 94305, United States
-
Xiangya Hospital Central South University
Changsha, Hu'nan, 410008, China